Skip to main content
Toggle Menu of ADA WebSites
ADA Websites
Partnerships and Commissions
Toggle Member Links
Toggle Menu
e-mail Print Share
Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy (August 2019 Article 3)
CE Credit(s):
1
Member Price:
$5.00
Retail Price:
$40.00
Description
Open Tabs
Description:

JADA August 2019

Background. The authors’ aim in this systematic review was to evaluate the validity of using preoperative serum C-terminal cross-linking telopeptide (CTX) levels as a predictive factor of increased risk of developing medication-related osteonecrosis of the jaw (MRONJ) in patients receiving bisphosphonate (BP) therapy who underwent invasive dental procedures.

Key Words. Bisphosphonate-associated osteonecrosis; clinical protocols; alveolar bone; bone.

Related Courses:
Web Test Course Details
More from the ADA: